世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ラジオ免疫療法-世界市場シェアとランキング、全体売上高と需要予測 2024-2030


Radioimmunotherapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

ラジオ免疫療法の世界市場は、2023年に1865百万米ドルの価値があると推定され、2024年から2030年の予測期間中に14.63%のCAGRで、2030年までに5408百万米ドルの再調整された規模になると予測されている。 ラジオ... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年2月26日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

ラジオ免疫療法の世界市場は、2023年に1865百万米ドルの価値があると推定され、2024年から2030年の予測期間中に14.63%のCAGRで、2030年までに5408百万米ドルの再調整された規模になると予測されている。
ラジオ免疫療法の北米市場は、2023年に1.1億ドルと評価され、2024年から2030年の予測期間中に14.13%のCAGRで、2030年までに3.274億ドルに達するだろう。
ラジオ免疫療法のアジア太平洋市場は、2023年に1億7,172万ドルと評価され、2024年から2030年の予測期間中に18.84%のCAGRで、2030年までに5億3,470万ドルに達するだろう。
放射線免疫療法の欧州市場は、2023年に5億7,441万ドルと評価され、2024年から2030年の予測期間中に14.48%のCAGRで、2030年までに1億5,8123万ドルに達するだろう。

ラジオ免疫療法の世界の主要企業には、バイエル、ノバルティス、ランテウス、オーロビンドファーマ、ムンディファーマ、中国アイソトープ&放射線、キュリウム製薬などが含まれる。2023年には、世界の大手5社が売上高で約99.45%のシェアを占めている。
本レポートは、ラジオ免疫療法の世界市場を包括的に紹介することを目的としており、ラジオ免疫療法の地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。
ラジオ免疫療法の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量的および定性的な分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、ラジオ免疫療法に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
バイエル
ノバルティス
ランテウス
オーロビンド・ファーマ
ムンディファーマ
中国アイソトープ・放射線
キュリウム・ファーマシューティカルズ
ギリアド・サイエンシズ
クラリティ・ファーマシューティカルズ
キュラサイト
ノルディック・ナノベクター
フィロゲン
ラジオメディックス
テリックス・ファーマシューティカルズ
オラノメッド
アクティニウム・ファーマシューティカルズ
Y-mAbsセラピューティクス
フュージョン・ファーマシューティカルズ

タイプ別セグメント
ベータ線放出
標的α療法

用途別セグメント
固形がん
非ホジキンリンパ腫

地域別
北米
米国
カナダ
メキシコ

アジア太平洋
中国
日本
韓国
東南アジア
インド
その他

ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
その他のヨーロッパ

南米
ブラジル
その他の南米諸国

中東・アフリカ
中東
アフリカ

各章の概要
第1章: レポートのスコープ、世界の総市場規模を紹介します。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:ラジオ免疫療法企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模と発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展の可能性をカバーし、読者が異なる下流市場でブルーオーシャン市場を見つけるのを助ける。
第5章:地域レベルでのラジオ免疫療法の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章 放射線免疫療法の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論

ページTOPに戻る


目次

1 Market Overview 1
1.1 Radioimmunotherapy Product Introduction 1
1.2 Global Radioimmunotherapy Market Size Forecast (2019-2030) 1
1.3 Radioimmunotherapy Market Trends & Drivers 3
1.3.1 Radioimmunotherapy Industry Trends 3
1.3.2 Radioimmunotherapy Market Drivers & Opportunity 5
1.3.3 Radioimmunotherapy Market Challenges 6
1.3.4 Radioimmunotherapy Market Restraints 7
1.4 Assumptions and Limitations 7
1.5 Study Objectives 8
1.6 Years Considered 9
2 Competitive Analysis by Company 10
2.1 Global Radioimmunotherapy Players Revenue Ranking (2023) 10
2.2 Global Radioimmunotherapy Revenue by Company (2019-2024) 11
2.3 Key Companies Radioimmunotherapy Area Served and Headquarters 12
2.4 Key Companies Radioimmunotherapy Product Offered 12
2.5 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 13
2.6 Radioimmunotherapy Market Competitive Analysis 13
2.6.1 Radioimmunotherapy Market Concentration Rate (2019-2024) 13
2.6.2 Global 5 Largest Companies by Radioimmunotherapy Revenue in 2023 14
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023) 15
2.7 Mergers & Acquisitions, Expansion 15
3 Segmentation by Type 17
3.1 Introduction by Type 17
3.1.1 Beta-emitting 17
3.1.2 Targeted Alpha Therapy 20
3.2 Global Radioimmunotherapy Sales Value by Type 21
3.2.1 Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030) 22
3.2.2 Global Radioimmunotherapy Sales Value, by Type (2019-2030) 23
3.2.3 Global Radioimmunotherapy Sales Value, by Type (%) (2019-2030) 24
4 Segmentation by Application 25
4.1 Introduction by Application 25
4.1.1 Solid Tumor 25
4.1.2 Non Hodgkin Lymphoma 27
4.2 Global Radioimmunotherapy Sales Value by Application 27
4.2.1 Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030) 28
4.2.2 Global Radioimmunotherapy Sales Value, by Application (2019-2030) 30
4.2.3 Global Radioimmunotherapy Sales Value, by Application (%) (2019-2030) 30
5 Segmentation by Region 32
5.1 Global Radioimmunotherapy Sales Value by Region 32
5.1.1 Global Radioimmunotherapy Sales Value by Region: 2019 VS 2023 VS 2030 32
5.1.2 Global Radioimmunotherapy Sales Value by Region (2019-2024) 32
5.1.3 Global Radioimmunotherapy Sales Value by Region (2025-2030) 33
5.1.4 Global Radioimmunotherapy Sales Value by Region (%), (2019-2030) 33
5.2 North America 34
5.2.1 North America Radioimmunotherapy Sales Value, 2019-2030 34
5.2.2 North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 35
5.3 Europe 36
5.3.1 Europe Radioimmunotherapy Sales Value, 2019-2030 36
5.3.2 Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 37
5.4 Asia Pacific 38
5.4.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030 38
5.4.2 Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023 VS 2030 39
5.5 South America 40
5.5.1 South America Radioimmunotherapy Sales Value, 2019-2030 40
5.5.2 South America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 40
5.6 Middle East & Africa 41
5.6.1 Middle East & Africa Radioimmunotherapy Sales Value, 2019-2030 41
5.6.2 Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 42
6 Segmentation by Key Countries/Regions 43
6.1 Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, 2019 VS 2023 VS 2030 43
6.2 Key Countries/Regions Radioimmunotherapy Sales Value, 2019-2030 44
6.3 North America 47
6.3.1 North America Radioimmunotherapy Sales Value, 2019-2030 47
6.3.2 North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 48
6.3.3 North America Radioimmunotherapy Sales Value by Application, 2023 VS 2030 49
6.4 Europe 50
6.4.1 Europe Radioimmunotherapy Sales Value, 2019-2030 50
6.4.2 Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 51
6.4.3 Europe Radioimmunotherapy Sales Value by Application, 2023 VS 2030 52
6.5 Asia Pacific 53
6.5.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030 53
6.5.2 Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 54
6.5.3 Asia Pacific Radioimmunotherapy Sales Value by Application, 2023 VS 2030 55
6.6 South America 56
6.6.1 South America Radioimmunotherapy Sales Value, 2019-2030 56
6.6.2 South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 57
6.6.3 South America Radioimmunotherapy Sales Value by Application, 2023 VS 2030 58
6.7 Middle East and Africa 59
6.7.1 Middle East and Africa Radioimmunotherapy Sales Value, 2019-2030 59
6.7.2 Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 60
6.7.3 Middle East and Africa Radioimmunotherapy Sales Value by Application, 2023 VS 2030 61
7 Company Profiles 62
7.1 Bayer 62
7.1.1 Bayer Company Details 62
7.1.2 Bayer Business Overview 62
7.1.3 Bayer Radioimmunotherapy Products and Services 63
7.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024) 64
7.1.5 Bayer Radioimmunotherapy SWOT Analysis 65
7.1.6 Bayer Business Strategy 65
7.2 Novartis 66
7.2.1 Novartis Company Details 66
7.2.2 Novartis Business Overview 67
7.2.3 Novartis Radioimmunotherapy Products and Services 67
7.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024) 69
7.2.5 Novartis Radioimmunotherapy SWOT Analysis 69
7.2.6 Novartis Business Strategy 70
7.3 Lantheus 70
7.3.1 Lantheus Company Details 71
7.3.2 Lantheus Business Overview 71
7.3.3 Lantheus Radioimmunotherapy Products and Services 72
7.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024) 72
7.3.5 Lantheus Radioimmunotherapy SWOT Analysis 73
7.3.6 Lantheus Business Strategy 74
7.4 Aurobindo Pharma 74
7.4.1 Aurobindo Pharma Company Details 75
7.4.2 Aurobindo Pharma Business Overview 75
7.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 76
7.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024) 76
7.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 77
7.4.6 Aurobindo Pharma Business Strategy 78
7.5 Mundipharma 78
7.5.1 Mundipharma Company Details 78
7.5.2 Mundipharma Business Overview 79
7.5.3 Mundipharma Radioimmunotherapy Products and Services 79
7.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024) 80
7.5.5 Mundipharma Business Strategy 81
7.6 China Isotope & Radiation 81
7.6.1 China Isotope & Radiation Company Details 81
7.6.2 China Isotope & Radiation Business Overview 82
7.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 82
7.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024) 83
7.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 83
7.6.6 China Isotope & Radiation Business Strategy 84
7.7 Curium Pharmaceuticals 85
7.7.1 Curium Pharmaceuticals Company Details 85
7.7.2 Curium Pharmaceuticals Business Overview 85
7.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 86
7.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024) 86
7.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 87
7.7.6 Curium Pharmaceuticals Business Strategy 88
7.8 Gilead Sciences 88
7.8.1 Gilead Sciences Company Details 89
7.8.2 Gilead Sciences Business Overview 89
7.8.3 Gilead Sciences Radioimmunotherapy Products and Services 90
7.8.4 Gilead Sciences Business Strategy 90
7.9 Clarity Pharmaceuticals 91
7.9.1 Clarity Pharmaceuticals Company Details 91
7.9.2 Clarity Pharmaceuticals Business Overview 91
7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 92
7.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 92
7.9.5 Clarity Pharmaceuticals Business Strategy 93
7.10 Curasight 93
7.10.1 Curasight Company Details 93
7.10.2 Curasight Business Overview 94
7.10.3 Curasight Radioimmunotherapy Products and Services 94
7.10.4 Curasight Radioimmunotherapy SWOT Analysis 95
7.10.5 Curasight Business Strategy 95
7.11 Nordic Nanovector 96
7.11.1 Nordic Nanovector Company Details 96
7.11.2 Nordic Nanovector Business Overview 97
7.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 97
7.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 98
7.11.5 Nordic Nanovector Business Strategy 98
7.12 Philogen 99
7.12.1 Philogen Company Details 99
7.12.2 Philogen Business Overview 100
7.12.3 Philogen Radioimmunotherapy Products and Services 100
7.12.4 Philogen Radioimmunotherapy SWOT Analysis 100
7.12.5 Philogen Business Strategy 101
7.13 RadioMedix 101
7.13.1 RadioMedix Company Details 101
7.13.2 RadioMedix Business Overview 102
7.13.3 RadioMedix Radioimmunotherapy Products and Services 102
7.13.4 RadioMedix Business Strategy 103
7.14 Telix Pharmaceuticals 103
7.14.1 Telix Pharmaceuticals Company Details 104
7.14.2 Telix Pharmaceuticals Business Overview 104
7.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 105
7.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 105
7.14.5 Telix Pharmaceuticals Business Strategy 106
7.15 Orano Med 106
7.15.1 Orano Med Company Details 107
7.15.2 Orano Med Business Overview 107
7.15.3 Orano Med Radioimmunotherapy Products and Services 108
7.15.4 Orano Med Radioimmunotherapy SWOT Analysis 108
7.15.5 Orano Med Business Strategy 108
7.16 Actinium Pharmaceuticals 109
7.16.1 Actinium Pharmaceuticals Company Details 109
7.16.2 Actinium Pharmaceuticals Business Overview 110
7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 110
7.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 111
7.16.5 Actinium Pharmaceuticals Business Strategy 111
7.17 Y-mAbs Therapeutics 112
7.17.1 Y-mAbs Therapeutics Company Details 112
7.17.2 Y-mAbs Therapeutics Business Overview 112
7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 113
7.17.4 Y-mAbs Therapeutics Business Strategy 113
7.18 Fusion Pharmaceuticals 114
7.18.1 Fusion Pharmaceuticals Company Details 114
7.18.2 Fusion Pharmaceuticals Business Overview 115
7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 115
7.18.4 Fusion Pharmaceuticals Business Strategy 116
8 Industry Chain Analysis 118
8.1 Radioimmunotherapy Industrial Chain 118
8.2 Radioimmunotherapy Upstream Analysis 119
8.2.1 Key Raw Materials 119
8.2.2 Raw Materials Key Suppliers 119
8.2.3 Manufacturing Cost Structure 119
8.3 Midstream Analysis 120
8.4 Downstream Analysis (Customers Analysis) 121
8.5 Sales Model and Sales Channels 123
8.5.1 Radioimmunotherapy Sales Model 123
8.5.2 Sales Channel 124
8.5.3 Radioimmunotherapy Distributors 125
9 Research Findings and Conclusion 126
10 Appendix 128
10.1 Research Methodology 128
10.1.1 Methodology/Research Approach 128
10.1.2 Data Source 131
10.2 Author Details 134
10.3 Disclaimer 134


 

ページTOPに戻る


 

Summary

The global market for Radioimmunotherapy was estimated to be worth US$ 1865 million in 2023 and is forecast to a readjusted size of US$ 5408 million by 2030 with a CAGR of 14.63% during the forecast period 2024-2030.
North American market for Radioimmunotherapy was valued at $ 1100 million in 2023 and will reach $ 3274 million by 2030, at a CAGR of 14.13% during the forecast period of 2024 through 2030.
Asia-Pacific market for Radioimmunotherapy was valued at $ 171.72 million in 2023 and will reach $ 534.7 million by 2030, at a CAGR of 18.84% during the forecast period of 2024 through 2030.
Europe market for Radioimmunotherapy was valued at $ 574.41 million in 2023 and will reach $ 1581.23 million by 2030, at a CAGR of 14.48% during the forecast period of 2024 through 2030.

The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately 99.45% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Radioimmunotherapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radioimmunotherapy by region & country, by Type, and by Application.
The Radioimmunotherapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioimmunotherapy.

Market Segmentation
By Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Segment by Type
Beta-emitting
Targeted Alpha Therapy

Segment by Application
Solid Tumor
Non Hodgkin Lymphoma

By Region
North America
United States
Canada
Mexico

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Other

Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe

South America
Brazil
Rest of South America

Middle East & Africa
Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Radioimmunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Radioimmunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Radioimmunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview 1
1.1 Radioimmunotherapy Product Introduction 1
1.2 Global Radioimmunotherapy Market Size Forecast (2019-2030) 1
1.3 Radioimmunotherapy Market Trends & Drivers 3
1.3.1 Radioimmunotherapy Industry Trends 3
1.3.2 Radioimmunotherapy Market Drivers & Opportunity 5
1.3.3 Radioimmunotherapy Market Challenges 6
1.3.4 Radioimmunotherapy Market Restraints 7
1.4 Assumptions and Limitations 7
1.5 Study Objectives 8
1.6 Years Considered 9
2 Competitive Analysis by Company 10
2.1 Global Radioimmunotherapy Players Revenue Ranking (2023) 10
2.2 Global Radioimmunotherapy Revenue by Company (2019-2024) 11
2.3 Key Companies Radioimmunotherapy Area Served and Headquarters 12
2.4 Key Companies Radioimmunotherapy Product Offered 12
2.5 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 13
2.6 Radioimmunotherapy Market Competitive Analysis 13
2.6.1 Radioimmunotherapy Market Concentration Rate (2019-2024) 13
2.6.2 Global 5 Largest Companies by Radioimmunotherapy Revenue in 2023 14
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023) 15
2.7 Mergers & Acquisitions, Expansion 15
3 Segmentation by Type 17
3.1 Introduction by Type 17
3.1.1 Beta-emitting 17
3.1.2 Targeted Alpha Therapy 20
3.2 Global Radioimmunotherapy Sales Value by Type 21
3.2.1 Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030) 22
3.2.2 Global Radioimmunotherapy Sales Value, by Type (2019-2030) 23
3.2.3 Global Radioimmunotherapy Sales Value, by Type (%) (2019-2030) 24
4 Segmentation by Application 25
4.1 Introduction by Application 25
4.1.1 Solid Tumor 25
4.1.2 Non Hodgkin Lymphoma 27
4.2 Global Radioimmunotherapy Sales Value by Application 27
4.2.1 Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030) 28
4.2.2 Global Radioimmunotherapy Sales Value, by Application (2019-2030) 30
4.2.3 Global Radioimmunotherapy Sales Value, by Application (%) (2019-2030) 30
5 Segmentation by Region 32
5.1 Global Radioimmunotherapy Sales Value by Region 32
5.1.1 Global Radioimmunotherapy Sales Value by Region: 2019 VS 2023 VS 2030 32
5.1.2 Global Radioimmunotherapy Sales Value by Region (2019-2024) 32
5.1.3 Global Radioimmunotherapy Sales Value by Region (2025-2030) 33
5.1.4 Global Radioimmunotherapy Sales Value by Region (%), (2019-2030) 33
5.2 North America 34
5.2.1 North America Radioimmunotherapy Sales Value, 2019-2030 34
5.2.2 North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 35
5.3 Europe 36
5.3.1 Europe Radioimmunotherapy Sales Value, 2019-2030 36
5.3.2 Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 37
5.4 Asia Pacific 38
5.4.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030 38
5.4.2 Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023 VS 2030 39
5.5 South America 40
5.5.1 South America Radioimmunotherapy Sales Value, 2019-2030 40
5.5.2 South America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 40
5.6 Middle East & Africa 41
5.6.1 Middle East & Africa Radioimmunotherapy Sales Value, 2019-2030 41
5.6.2 Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030 42
6 Segmentation by Key Countries/Regions 43
6.1 Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, 2019 VS 2023 VS 2030 43
6.2 Key Countries/Regions Radioimmunotherapy Sales Value, 2019-2030 44
6.3 North America 47
6.3.1 North America Radioimmunotherapy Sales Value, 2019-2030 47
6.3.2 North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 48
6.3.3 North America Radioimmunotherapy Sales Value by Application, 2023 VS 2030 49
6.4 Europe 50
6.4.1 Europe Radioimmunotherapy Sales Value, 2019-2030 50
6.4.2 Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 51
6.4.3 Europe Radioimmunotherapy Sales Value by Application, 2023 VS 2030 52
6.5 Asia Pacific 53
6.5.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030 53
6.5.2 Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 54
6.5.3 Asia Pacific Radioimmunotherapy Sales Value by Application, 2023 VS 2030 55
6.6 South America 56
6.6.1 South America Radioimmunotherapy Sales Value, 2019-2030 56
6.6.2 South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 57
6.6.3 South America Radioimmunotherapy Sales Value by Application, 2023 VS 2030 58
6.7 Middle East and Africa 59
6.7.1 Middle East and Africa Radioimmunotherapy Sales Value, 2019-2030 59
6.7.2 Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030 60
6.7.3 Middle East and Africa Radioimmunotherapy Sales Value by Application, 2023 VS 2030 61
7 Company Profiles 62
7.1 Bayer 62
7.1.1 Bayer Company Details 62
7.1.2 Bayer Business Overview 62
7.1.3 Bayer Radioimmunotherapy Products and Services 63
7.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024) 64
7.1.5 Bayer Radioimmunotherapy SWOT Analysis 65
7.1.6 Bayer Business Strategy 65
7.2 Novartis 66
7.2.1 Novartis Company Details 66
7.2.2 Novartis Business Overview 67
7.2.3 Novartis Radioimmunotherapy Products and Services 67
7.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024) 69
7.2.5 Novartis Radioimmunotherapy SWOT Analysis 69
7.2.6 Novartis Business Strategy 70
7.3 Lantheus 70
7.3.1 Lantheus Company Details 71
7.3.2 Lantheus Business Overview 71
7.3.3 Lantheus Radioimmunotherapy Products and Services 72
7.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024) 72
7.3.5 Lantheus Radioimmunotherapy SWOT Analysis 73
7.3.6 Lantheus Business Strategy 74
7.4 Aurobindo Pharma 74
7.4.1 Aurobindo Pharma Company Details 75
7.4.2 Aurobindo Pharma Business Overview 75
7.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 76
7.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024) 76
7.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 77
7.4.6 Aurobindo Pharma Business Strategy 78
7.5 Mundipharma 78
7.5.1 Mundipharma Company Details 78
7.5.2 Mundipharma Business Overview 79
7.5.3 Mundipharma Radioimmunotherapy Products and Services 79
7.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024) 80
7.5.5 Mundipharma Business Strategy 81
7.6 China Isotope & Radiation 81
7.6.1 China Isotope & Radiation Company Details 81
7.6.2 China Isotope & Radiation Business Overview 82
7.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 82
7.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024) 83
7.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 83
7.6.6 China Isotope & Radiation Business Strategy 84
7.7 Curium Pharmaceuticals 85
7.7.1 Curium Pharmaceuticals Company Details 85
7.7.2 Curium Pharmaceuticals Business Overview 85
7.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 86
7.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024) 86
7.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 87
7.7.6 Curium Pharmaceuticals Business Strategy 88
7.8 Gilead Sciences 88
7.8.1 Gilead Sciences Company Details 89
7.8.2 Gilead Sciences Business Overview 89
7.8.3 Gilead Sciences Radioimmunotherapy Products and Services 90
7.8.4 Gilead Sciences Business Strategy 90
7.9 Clarity Pharmaceuticals 91
7.9.1 Clarity Pharmaceuticals Company Details 91
7.9.2 Clarity Pharmaceuticals Business Overview 91
7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 92
7.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 92
7.9.5 Clarity Pharmaceuticals Business Strategy 93
7.10 Curasight 93
7.10.1 Curasight Company Details 93
7.10.2 Curasight Business Overview 94
7.10.3 Curasight Radioimmunotherapy Products and Services 94
7.10.4 Curasight Radioimmunotherapy SWOT Analysis 95
7.10.5 Curasight Business Strategy 95
7.11 Nordic Nanovector 96
7.11.1 Nordic Nanovector Company Details 96
7.11.2 Nordic Nanovector Business Overview 97
7.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 97
7.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 98
7.11.5 Nordic Nanovector Business Strategy 98
7.12 Philogen 99
7.12.1 Philogen Company Details 99
7.12.2 Philogen Business Overview 100
7.12.3 Philogen Radioimmunotherapy Products and Services 100
7.12.4 Philogen Radioimmunotherapy SWOT Analysis 100
7.12.5 Philogen Business Strategy 101
7.13 RadioMedix 101
7.13.1 RadioMedix Company Details 101
7.13.2 RadioMedix Business Overview 102
7.13.3 RadioMedix Radioimmunotherapy Products and Services 102
7.13.4 RadioMedix Business Strategy 103
7.14 Telix Pharmaceuticals 103
7.14.1 Telix Pharmaceuticals Company Details 104
7.14.2 Telix Pharmaceuticals Business Overview 104
7.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 105
7.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 105
7.14.5 Telix Pharmaceuticals Business Strategy 106
7.15 Orano Med 106
7.15.1 Orano Med Company Details 107
7.15.2 Orano Med Business Overview 107
7.15.3 Orano Med Radioimmunotherapy Products and Services 108
7.15.4 Orano Med Radioimmunotherapy SWOT Analysis 108
7.15.5 Orano Med Business Strategy 108
7.16 Actinium Pharmaceuticals 109
7.16.1 Actinium Pharmaceuticals Company Details 109
7.16.2 Actinium Pharmaceuticals Business Overview 110
7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 110
7.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 111
7.16.5 Actinium Pharmaceuticals Business Strategy 111
7.17 Y-mAbs Therapeutics 112
7.17.1 Y-mAbs Therapeutics Company Details 112
7.17.2 Y-mAbs Therapeutics Business Overview 112
7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 113
7.17.4 Y-mAbs Therapeutics Business Strategy 113
7.18 Fusion Pharmaceuticals 114
7.18.1 Fusion Pharmaceuticals Company Details 114
7.18.2 Fusion Pharmaceuticals Business Overview 115
7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 115
7.18.4 Fusion Pharmaceuticals Business Strategy 116
8 Industry Chain Analysis 118
8.1 Radioimmunotherapy Industrial Chain 118
8.2 Radioimmunotherapy Upstream Analysis 119
8.2.1 Key Raw Materials 119
8.2.2 Raw Materials Key Suppliers 119
8.2.3 Manufacturing Cost Structure 119
8.3 Midstream Analysis 120
8.4 Downstream Analysis (Customers Analysis) 121
8.5 Sales Model and Sales Channels 123
8.5.1 Radioimmunotherapy Sales Model 123
8.5.2 Sales Channel 124
8.5.3 Radioimmunotherapy Distributors 125
9 Research Findings and Conclusion 126
10 Appendix 128
10.1 Research Methodology 128
10.1.1 Methodology/Research Approach 128
10.1.2 Data Source 131
10.2 Author Details 134
10.3 Disclaimer 134


 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20 10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る